Nihon Kohden (OTCMKTS:NHNKY) Shares Gap Down – Here’s Why

Shares of Nihon Kohden Corporation (OTCMKTS:NHNKY) gapped down prior to trading on Friday . The stock had previously closed at $8.72, but opened at $8.2910. Nihon Kohden shares last traded at $8.38, with a volume of 7,415 shares changing hands.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Nihon Kohden to a “hold” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Nihon Kohden presently has an average rating of “Buy”.

Nihon Kohden Stock Performance

The stock’s fifty day moving average price is $9.28 and its 200-day moving average price is $10.19. The firm has a market cap of $1.43 billion, a PE ratio of 14.20 and a beta of 0.39.

Nihon Kohden (OTCMKTS:NHNKY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.10. The firm had revenue of $453.10 million for the quarter, compared to analysts’ expectations of $414.40 million. Nihon Kohden had a net margin of 6.08% and a return on equity of 9.48%. Sell-side analysts forecast that Nihon Kohden Corporation will post 0.61 earnings per share for the current fiscal year.

Nihon Kohden Company Profile

Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.